Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
2 competitors in Metastatic Pancreatic Adenocarcinoma
View Full LandscapeTarget Indication
Metastatic Pancreatic Adenocarcinoma
Clinical Trial
NCT05102721Last updated: 12/4/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Bavencio
Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.
View on EMAHuman Papillomavirus (HPV) Infection
HPV InfectioN
Norovirus Infections
Alzheimer Disease
Carcinoma, Non-Small-Cell Lung